Aseptic vitrification of human germinal vesicle oocytes using dimethyl sulfoxide as a cryoprotectant

Fertil Steril. 2006 Mar;85(3):741-7. doi: 10.1016/j.fertnstert.2005.08.047.

Abstract

Objective: To evaluate the viability of vitrified human germinal vesicle (GV)-oocytes to mature to metaphase II (MII) stage after "rapid" cooling directly in liquid nitrogen in comparison with "slow" cooling in a closed 0.5-mL straw (aseptic system), with or without dimethyl sulfoxide (DMSO) in vitrification solution. The possibility of avoiding parthenogenesis of the oocytes after vitrification using DMSO was investigated.

Design: In vitro maturation after vitrification.

Setting: Assisted reproduction centers.

Patient(s): Patients undergoing standard superovulation treatment and having GV-oocytes after follicular puncture.

Intervention(s): The GV-oocytes were vitrified with long/short exposure to DMSO using slow or rapid cooling, then warmed and matured in vitro.

Main outcome measure(s): Maturation after warming.

Result(s): Oocyte development up to MII stage after vitrification with DMSO was 71% in the group with "rapid" cooling, and in groups with "slow" cooling, 68% and 72% for long and short exposure to DMSO, respectively. The maturation rate of GV-oocytes after slow cooling without DMSO was 51%. In the vitrification with long-term contact of oocytes with DMSO group, a high rate of parthenogenesis was observed. When vitrification with short-term contact of oocytes with DMSO at room temperature was used, no parthenogenesis was observed.

Conclusion(s): Cryopreservation of human GV-oocytes in open-pulled straws OPS) using an aseptic slow cooling method gives high maturation rates but only in combination with DMSO. To avoid spontaneous parthenogenesis, the exposure to DMSO must occur for a reduced time and at room temperature.

Publication types

  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Asepsis*
  • Cell Survival / drug effects
  • Cellular Senescence / drug effects
  • Cryopreservation / methods*
  • Cryoprotective Agents / administration & dosage
  • Cryoprotective Agents / pharmacology*
  • Dimethyl Sulfoxide / administration & dosage
  • Dimethyl Sulfoxide / pharmacology*
  • Drug Administration Schedule
  • Female
  • Humans
  • Metaphase
  • Oocytes / cytology
  • Oocytes / drug effects*
  • Oocytes / physiology
  • Parthenogenesis / drug effects
  • Time Factors

Substances

  • Cryoprotective Agents
  • Dimethyl Sulfoxide